— 

This bulletin provides direction to use another ICD-10-CA emergency use code, per the World Health Organization, to identify cases of multisystem inflammatory syndrome associated with COVID-19.

In Canada, U07.3 Emergency use of U07.3 will be used to 

  • Classify cases of multisystem inflammatory syndrome (MIS) associated with COVID-19.

The diagnosis of multisystem inflammatory syndrome associated with COVID-19 can be found in children and adults.

Note: There is no change to the previous ICD-10-CA coding direction for use of U07.1 COVID-19, virus identified or U07.2 COVID-19, virus not identified.

New direction

When the physician/primary care provider makes the diagnosis of multisystem inflammatory syndrome associated with COVID-19,

  • Assign U07.3 Multisystem inflammatory syndrome associated with COVID-19, mandatory, as diagnosis type (M, 1, 2, 3, W, X, Y)/main problem or other problem, depending on the circumstances surrounding the episode of care.

If facilities are able to identify previously submitted abstracts that had a diagnosis of multisystem inflammatory syndrome associated with COVID-19 (see examples of synonyms below), it is recommended to correct the code assignment and resubmit to align with the above direction.

The following tabular listing changes will be included in the ICD-10-CA v2022 (subject to minor changes prior to release).

U07.3 Multisystem inflammatory syndrome associated with COVID-19

Temporally associated with COVID-19:

  • Cytokine storm (syndrome)
  • Kawasaki-like syndrome
  • Paediatric Inflammatory Multisystem Syndrome [PIMS]
  • Multisystem Inflammatory Syndrome in Children [MIS-C]

Excludes: mucocutaneous lymph node syndrome [Kawasaki] (M30.3)


Note: For clients who have a v2018 Shadow file (.sdw) of ICD-10-CA, it is recommended that a note be added at U07.3 to reflect the direction outlined in the bulletins.

eQuery

Clients can find answers to COVID-19–related questions submitted to eQuery by searching eQuery on keywords “U07.1,” “U07.2,” “U07.3” or “COVID-19.” If you require assistance with coding a specific case, submit your question and pertinent clinical documentation via eQuery.

Explore CIHI’s COVID-19 resources web page, with key reports and resources on the coronavirus disease (COVID-19) pandemic.

Data capture of COVID-19–related documentation using CED-DxS

U07.3 and the accompanying common term will be added to the Canadian Emergency Department Diagnosis Shortlist (CED-DxS). CED-DxS v7.1 will be released to clients in November 2020.

  • U07.3 Multisystem inflammatory syndrome associated with COVID-19

The CED-DxS is used to capture ED Discharge Diagnoses (NACRS data element 137).

Send your questions about the CED-DxS to nacrspicklists@cihi.ca.

Case-mix grouping methodologies

Code U07.3 will be added to the CMG+ and CACS methodologies for 2021. As a result, data on U07.3 cases collected in 2020–2021 will group appropriately only after it has been regrouped to the 2021 methodology. Until then, if this code is reported as the most responsible diagnosis, main problem or ED discharge diagnosis, these cases will group to CMG 999: Ungroupable, or CACS Z999: Ungroupable.

Send your questions about case mix to casemix@cihi.ca.